Xencor (XNCR) Tops Q2 EPS by 43c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St futures gain as chip stocks extend recovery; earnings in focus
- Oil prices rise nearly 2% on fresh attacks by US and Iran
- Chip stocks extend global rebound following last week's rout
- Adobe, Salesforce and Intuit fall as Morgan Stanley begins cautious coverage
- Danaher shares tumble despite earnings beat
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Xencor Reports Second Quarter 2023 Financial Results
August 3, 2023 4:01 PM EDT-- Management to Host Conference Call at 4:30 p.m. ET Today --
PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2023 and provided a review of recent business and clinical highlights.
In the past quarter we continued to advance a clinical portfolio of XmAb drug candidates, enrolling patients across multiple Phase 1 and Phase 2 studies in oncology and autoimmune... More
